Table 3. Clinical data for subjects.

Subject	Age	HA Severity	Baseline FVIII	Peak Titer(BU/ml)a	Inhibitor Treatment History	Hemophilia Genotype(if known)
Predominantly IgG1 Response
17A	24	mild	6–14%	250	ITI failedb	A2201P
N-008	2	moderate	3%	11	no ITI	14–21 delc
L-006	2	moderate	1%	87	ITI initiated	R2304C
Predominantly IgG4 Response
F-014	19	severe	<1%	32	ITI partly successful	int-22 invd
B-002	20	severe	<1%	667	ITI failed	9–11 dele
A-002	14	severe	<1%	256	ITI failed	not inversionf
Mixed IgG Subtype Response
G-004	16	severe	<1%	1000+	no ITI	int-22 inv
C-010	27	severe	<1%	80	ITI partly successful	not inversion
D-006	10	severe	<1%	496	ITI failed	not inversion
L-025	35	severe	<1%	191	no ITI	not inversion
P-011	8	severe	<1%	1084.4	ITI failed	int-22 inv
P-001	12	severe	<1%	308.7	ITI failed	int-22 inv
F-006	27	severe	<0.25%	44	no ITI	int-22 inv
A-008	31	severe	<1%	86	ITI successful	int-22 inv
F-025	21	severe	<1%	43.8	ITI failed	int-22 inv
C-019	60	severe	<1%	336	ITI failed	int-22 inv
C-028	2	severe	<1%	96	ITI failed	not inversion
Secondary and primary SPR binding signals (in RU) do not match
H-001	50	severe	<1%	742	no ITI	int-22 inv
Autoimmune subjects
Q-011	77	autoimmune	normal	6	prednisone	autoimmune
Q-012	77	autoimmune	normal	2	prednisone	autoimmune
Q-033	79	autoimmune	normal	39	prednisone	autoimmune
Q-016	62	autoimmune	normal	20	prednisone	autoimmune

^aBU/ml = Bethesda Units/milliliter;

^bITI = Immune Tolerance Induction;

^c14–21del = exons 14–21 deleted;

^dint-22 inv = intron 22 inversion;

^e9–11del = exons 9–11 deleted;

^fnot inversion = not an intron-22 or intron-1 inversion mutation.